Human visceral adipose tissue and the plasminogen activator inhibitor type 1

Objective: The objective of this study was to systematically evaluate the molecular basis of the association between visceral fat mass and plasma plasminogen activator inhibitor-1 (PAI-1) levels in man. Design: A comprehensive approach comprising observational, in vitro, and human intervention studies. Measurements and results: We confirmed an exclusive relationship between visceral fat and plasma PAI-1 levels (r=0.79, P<0.001) and corroborated preferential PAI-1 release from adipose tissue explants. Yet, messenger RNA analysis and in vivo measurement of PAI-1 release from visceral fat (AV-differences over the omentum) not only excluded visceral adipose tissue as a relevant source of circulating PAI-1, but also excluded visceral fat as a significant source of proinflammatory mediators such as tumor necrosis factor-α, IL-1 or transforming growth factor-β that could induce PAI-1 expression in tissues other than visceral fat. Short-term interventions with acipimox and growth hormone (GH) as well as statistical evaluation excluded free fatty acids and GH as metabolic links. Further analysis of the metabolic data in a stepwise regression model indicated that plasma PAI-1 levels and visceral fat rather are co-correlates that both relate to impaired lipid handling. Conclusion: Our PAI-1 studies show that visceral fat mass and plasma PAI-1 levels are co-correlated rather than causatively related, with lipid load as common denominator. © 2007 Nature Publishing Group All rights reserved.
Chemicals / CAS: acipimox, 51037-30-0; growth hormone, 36992-73-1, 37267-05-3, 66419-50-9, 9002-72-6; plasminogen activator inhibitor 1, 140208-23-7; Cytokines; Human Growth Hormone, 12629-01-5; Inflammation Mediators; Plasminogen Activator Inhibitor 1; RNA, Messenger; SERPINE1 protein, human; Tumor Necrosis Factor-alpha